Análisis Argos
ABBV
ABBVCara1 señal de riesgo
AbbVie Inc. · Healthcare
US$ 263.48
precio al 2026-07-28
Valor justo Argos*
US$ 158–177
vs. su valor justo
49% por encima
Score Argos
49/100
LA RESPUESTA
El mercado le pide crezca 14.9% al año — más de lo que ha demostrado (2.4%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Retorno sobre el capital alto (21%).
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
!Altman Z'' en zona roja (-0.09)
VALOR2/6FUTURO3/6PASADO6/6SALUD2/6DIVIDENDO3/6
El Iris de calidad
VALOR2/6FUTURO3/6PASADO6/6SALUD2/6DIVIDENDO3/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance razonable
DividendoRetorno al accionista moderado
Score Argos49de 100Cara
Ingresos▲9%
US$ 61.2 B
Margen operativo▲102%
32.8%
Flujo de caja libre▼0%
US$ 17.8 B
Deuda neta
US$ 63.8 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 465.5B
P/E110.2x
EV/EBITDA18.8x
FCF yield3.8%
ROIC21.3%
Margen operativo32.8%
Crecim. ingresos+8.6%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

fool.com · 11 jul
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
AbbVie has a portfolio of attractive drugs, including branded products that are off-patent but still highly profitable. The company's acquisition of Apogee helps expand its drug pipeline.
gurufocus.com · 10 jul
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100
On July 10, 2026, AbbVie Inc (ABBV) shares fell 0.7% to a current price of $248.08. This price is down from a 52-week high of $261.64 and remains significantly
247wallst.com · 10 jul
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that reshape how income investors should think about big pharma.
zacks.com · 9 jul
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, AbbVie (ABBV) stood at $249.91, denoting a -1.12% move from the preceding trading day.
zacks.com · 9 jul
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.
fool.com · 9 jul
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
zacks.com · 7 jul
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
cnbc.com · 7 jul
Buy these quality, low-stress stocks for the summer, says Jefferies
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more than 70% since 2024, close to levels seen during the 1990s dot-com era.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.